Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Licenses Disease Gene to Commercial Lab for Risk Test

NEW YORK, Oct. 10 - Variagenics said today it granted nonexclusive commercialization rights to ARUP Laboratories to develop a home brew test for an allele associated with risk for cardiovascular disease.

 

Variations in the human methylenetetrahydrofolate reductase gene are associated with increased risk for cardiovascular disease, central nervous system disorders, osteoporosis, disorders influenced by folic acid metabolism, and cancer, according to Variagenics.

 

Financial details of the agreement with ARUP, a full-service clinical reference laboratory based in Salt Lake City, were not disclosed.

 

Variagenics obtained patent rights for the MTHFR gene in 1999 from McGillUniversity.

 

Click here for more information.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.